Literature DB >> 11273675

Latanoprost exerts neuroprotective activity in vitro and in vivo.

F Drago1, S Valzelli, I Emmi, A Marino, C C Scalia, V Marino.   

Abstract

Prostaglandins may influence cyclo-oxygenase (COX-2) and nitric oxide (NO) synthase activity, thus interfering with ischemia-induced neurotoxic processes. The prostaglandin synthetic derivative, latanoprost was tested in different in vivo and in vitro models of neuronal damage in order to study its influence on these processes. Ischemia was induced in rats by bilateral occlusion of the carotid arteries for 30 min. Latanoprost (0.01 mg x kg(-1)per die, i.p. for 3 days) or the ionotropic glutamate receptors antagonist, MK-801 (0.1 mg x kg(-1)per die, i.p. for 3 days) were equal in preventing lactate accumulation in retinal tissue of animals subjected to acute ischemia. Similar results were obtained in animals with retinal ischemia induced by increasing intraocular pressure to 120 mm Hg for 45 min. PGF2alpha, PGE2, latanoprost and acid of latanoprost (PhXA85) reduced the release of LDH from primary cultures of human retinal cells in vitro subjected to glutamate (10 microM) or hypoxia/re-oxygenation exposure. This effect was observed only at concentrations of 1-0.01 microM for PGF2alpha and PGE2, and of 0.1-0.001 microM for latanoprost (0.01 microM-0.1 nM for PhXA85). The COX-2 activity in cultured retinal cells exposed to glutamate was measured as PGE2 production when latanoprost was applied compared to arachidonic acid (AA) at different molar concentrations. The COX-2 activity was reduced by arachidonic acid (0.1-0.01 microM) as well as by latanoprost (0.1-0.001 microM) and PhXA85 (0.01-0.001 microM) in retinal cells exposed to glutamate. Inhibition of inducible NO synthase was also found with the same drug concentrations. These results suggest that latanoprost exerts a neuroprotective activity in vitro and in vivo. This effect seems to be present only at low concentrations of the drug. A negative feedback on neuronal COX-2 activity may be possibly involved.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273675     DOI: 10.1006/exer.2000.0975

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  15 in total

1.  Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway.

Authors:  Jun Zheng; Xuemei Feng; Lina Hou; Yongyao Cui; Liang Zhu; Jian Ma; Zheng Xia; Wei Zhou; Hongzhuan Chen
Journal:  Cell Mol Neurobiol       Date:  2011-01-29       Impact factor: 5.046

2.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

3.  Neuroprotective effect of latanoprost on rat retinal ganglion cells.

Authors:  Hideyo Kudo; Toru Nakazawa; Masahiko Shimura; Hidetoshi Takahashi; Nobuo Fuse; Kenji Kashiwagi; Makoto Tamai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

4.  Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells.

Authors:  Shinichiro Saito; Masaaki Ohashi; Akira Naito; Yasuhiro Fukaya; Yasuyuki Suzuki; Makoto Araie
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

5.  Suppression of rat retinal ganglion cell death by PACAP following transient ischemia induced by high intraocular pressure.

Authors:  Tamotsu Seki; Hiroyuki Itoh; Tomoya Nakamachi; Kimi Endo; Yoshihiro Wada; Keisuke Nakamura; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-06-29       Impact factor: 3.444

Review 6.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Chronic bilateral common carotid artery occlusion: a model for ocular ischemic syndrome in the rat.

Authors:  Daniel Lavinsky; Nice Sarmento Arterni; Matilde Achaval; Carlos Alexandre Netto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

Review 8.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Intraocular pressure fluctuation and neurodegeneration in the diabetic rat retina.

Authors:  Kyoung In Jung; Jung Eun Woo; Chan Kee Park
Journal:  Br J Pharmacol       Date:  2020-04-15       Impact factor: 8.739

10.  Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.

Authors:  Akiyasu Kanamori; Maiko Naka; Masahide Fukuda; Makoto Nakamura; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-24       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.